NFKB1 and Burkitt lymphoma: Previously, digoxin was found to inhibit the activation of the NF-κB pathway in Raji human Burkitt’s lymphoma cells, indicating that this cardiac glycoside may target NF-κB to mediate its antitumor activity [42].